Latest news for AEye (NASDAQ:LIDRW) Stock

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

AEye Inc

Investment lays groundwork for potential large-scale uranium enrichment expansion
BETHESDA, Md., Nov. 20, 2024 /PRNewswire/ -- Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) today announced that it is resuming centrifuge manufacturing activities and expanding its manufacturing capacity at its facility in Oak Ridge, Tennessee.&nbsp; The company will invest an additional approximately $60 million for this effort over the next 18 months to lay the groundwork to support a potential large-scale expansion of uranium enrichment at the Centrus' American Centrifuge Plant in Piketon, Ohio.&nbsp; Such a large-scale expansion would require a multi-billion dollar public and private investment.&nbsp;
This announcement follows Centrus' recent success in securing over $2 billion in contingent purchase commitments from customers to support future production of Low-Enriched Uranium (LEU), as well as two awards from the U.S. Department of Energy aimed at enrichment and deconversion of High-Assay, Low-Enriched Uranium (HALEU).

News

Contracts

Centrus Energy To Invest An Additional ~$60M For This Effort Over The Next 18-Months To Lay The Groundwork To Support A Potential Large-Scale Expansion Of Uranium Enrichment At The Centrus' American Centrifuge Plant In Piketon, Ohio

TJX CEO Says Import Tariff Hikes Won't Affect Company Much Due To Smaller Direct Import Business

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies.
iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at Kyoto University. The core technology to differentiate iPSC into immune cells originates from CiRA's Shin Kaneko's laboratory. iCAR-T has potential to develop ‘off-the-shelf' cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy.

Biotech

General

Alloy Therapeutics Signs Collaboration And License Agreement With Takeda To Develop Takeda's Proprietary Induced Pluripotent Stem Cell Derived CAR-T Cell Platform And iPSC-Derived CAR-NK Platform

WIIM

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific shares are trading higher after the company announced its purchase agreements and land lease amendments were approved by the Denton City Council.

In the current market session, Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) stock price is at $60.91, after a 3.29% drop. However, over the past month, the company's stock increased by 42.41%, and in the past year, by 215.90%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1732120212_0.png" alt="Past Year Chart" />

<h3>Palantir Technologies P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Palantir Technologies has a better P/E ratio of 314.9 than the aggregate P/E ratio of 74.07 of the Software industry. Ideally, one might believe that Palantir Technologies Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732120212_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

PLTR

P/E Ratio Insights for Palantir Technologies

Keefe, Bruyette &amp; Woods analyst Bose George downgrades Federal National Mortgage (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FNMA#OTC">FNMA</a>) from Outperform to Market Perform and raises the price target from $2 to $3.

Downgrades

Price Target

Analyst Ratings

FNMA

Keefe, Bruyette & Woods Downgrades Federal National Mortgage to Market Perform, Raises Price Target to $3

<a href="https://muddywatersresearch.com/wp-content/uploads/2024/11/ELF_Report_20241120_Final.pdf" title="https://muddywatersresearch.com/wp-content/uploads/2024/11/ELF_Report_20241120_Final.pdf">https://muddywatersresearch.com/wp-content/uploads/2024/11/ELF_Report_20241120_Final.pdf</a>

Short Sellers

Trading Ideas

Watching e.l.f. Beauty; Muddy Waters Research Issues Report Titled "e.l.f. Beauty, Inc. A Revenue and Inventory Mystery"

PureCycle Technologies shares are trading higher after TD Cowen maintained a Buy rating on the stock and raised its price target from $10 to $15.

Bethesda's Starfield has reached 15 million players since its release in<a href="https://www.benzinga.com/general/gaming"> September 2023. </a>
The game launched with six million players on its first day, making it Bethesda Game Studios' most successful launch, surpassing The Elder Scrolls V: Skyrim and Fallout 4. Its availability on Xbox Game Pass from day one played a significant role in its rapid growth.
See Also: <a href="https://www.benzinga.com/top-stories/24/11/42072274/xbox-game-pass-brings-big-titles-in-late-november-including-stalker-microsoft-flight-simulator-2024">Xbox Game Pass Brings Big Titles In Late November, Including Stalker, Microsoft Flight Simulator 2024</a>
&#8220;We&#8217;re thrilled that so many of you have embarked on this journey with us, and we appreciate your feedback,&#8221; Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Bethesda<a href="https://bethesda.net/en/game/starfield/article/mqjRpu4DgOPKOdHE20SC1/starfields-november-update-is-now-live"> said</a> in a statement on its website.
To mark the milestone, Bethesda released Update 1.14.74, which includes gameplay adjustments, bug fixes, and new content. The update introduces the Deimog, a land vehicle described as "built for speed and endurance," with features like a fully enclosed cabin and a rocket launcher for defense.
A new quest, The Perfect Recipe, was also added. The story takes players to Akila City, where they assist Harbhajan, a mechanic with a hidden passion for cooking, by returning a lost recipe book that could help him pursue his dream of becoming a renowned chef.
<h3 class="wp-block-heading">New Features For Gamers</h3>
Update 1.14.74 also brought significant quality-of-life improvements and changes:
<ul>
<li>Uncapped Frame Rate: Xbox Series X players can now enable this option for smoother gameplay.</li>
<li>Achievement Compatibility: Creations by Verified Creators are now achievement-friendly, though achievements won't retroactively unlock on prior saves.</li>
<li>Enhanced Creation Kit: Lipsync animation data generation is now available, making modding easier for creators.</li>
</ul>
Bethesda has also addressed several gameplay and quest bugs, ensuring smoother experiences for players navigating its vast universe.
<h3 class="wp-block-heading">Mixed Reception For Shattered Space</h3>
While the updates are widely welcomed, Bethesda's first Starfield expansion, Shattered Space, has faced criticism. 
Despite being billed as a return to form, the expansion currently holds a &#8220;mostly negative&#8221; rating on Steam, with some players expressing disappointment in its execution. 
According to Xbox head Phil Spencer, Bethesda's Todd Howard had even questioned whether to delay the expansion for a more impactful launch.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42013601/phil-spencer-responds-to-this-is-an-xbox-criticism-were-in-the-middle-of-a-transition">Phil Spencer Responds To &#8216;This Is An Xbox&#8217; Criticism: &#8216;We&#8217;re In The Middle Of A Transition&#8217;</a></li>
</ul>
Image credits: Shutterstock.

Gaming

MSFT

Starfield Reaches 15 Million Players With Updates, New Content

LNTH

Lantheus Holdings shares are trading higher after the company announced its board authorized a $250 million share repurchase program.

Keefe, Bruyette &amp; Woods analyst Bose George downgrades Federal Home Loan (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FMCC#OTC">FMCC</a>) from Outperform to Market Perform and raises the price target from $2.5 to $4.

FMCC

Keefe, Bruyette & Woods Downgrades Federal Home Loan to Market Perform, Raises Price Target to $4

INSP

Inspire Medical Systems shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $220 to $255.

Macro Economic Events

Macro Notification

Economics

Goldman Sachs CEO David Solomon Says There's A Belief That The New Administration Will Pare Back The Level Of Regulation; Capital Investment Markets Activity Is Picking Up; In 2025, We Will Have More Robust Capital Markets; Not Spoken Directly With President-Elect Trump; Should Have A Consistent Process Around Stress Testing; Market Is Responding To The Idea That The New Administration Is Pro-Growth

RBC Capital analyst Scott Hanold maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Outperform and lowers the price target from $185 to $180.

CHRD

RBC Capital Maintains Outperform on Chord Energy, Lowers Price Target to $180

Village Farms International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) and Hemp for Victory filed a joint motion seeking to disqualify the Drug Enforcement Administration (DEA) from defending the proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
The parties argue that the DEA is compromised and opposes the rescheduling, suggesting its role should be taken by the Department of Justice (DOJ) to ensure an impartial process.
"It is our belief that the DEA cannot lawfully act as the proponent of the Proposed Rule and that its actions throughout the administrative process demonstrate that it opposes the proposed transfer of marijuana to Schedule III and is therefore compromised," Shane Pennington, partner at Porter Wright Morris &amp; Arthur, LLP and counsel to Village Farms and Hemp for Victory commented, "Treating the DEA as the proponent of the Proposed Rule would violate APA and DEA regulations and render these proceedings a sham. Lawyers from the Department of Justice, not the Drug Enforcement Administration, must therefore defend this rule."
In August 2023, Health and Human Services (HHS) Secretary Xavier Becerra confirmed his agency responded to President Biden&#8217;s directive to provide scheduling recommendations for cannabis to the DEA. HHS <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">called for marijuana to be reclassified as a Schedule III drug</a> under the Controlled Substances Act.
The <a href="https://villagefarms.com/wp-content/uploads/2024/11/Hemp-for-Victory-and-Village-Farms-Motion-to-Disqualify-and-Supplement-Record-with-Exhibits-A-C.pdf">motion</a> argues that "Not once in its history as an agency had DEA ever rejected an HHS scheduling recommendation. This time, however, DEA did not just disagree with HHS's views, it opposed them so vehemently that the Attorney General had to refer the interagency dispute to the Office of Legal Counsel for resolution."
Read Also: <a href="https://www.benzinga.com/general/health-care/24/11/42077935/trump-picks-dr-oz-who-says-seniors-should-give-medical-marijuana-a-try-to-lead-centers-for-medicare-and-medicaid-services">Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Calling For Transparency</h2>
The motion also asks that the record include all requests for hearing and/or participation in these proceedings filed with the DEA; a record of the decisions made by the Administrator regarding why certain parties were designated as participants and others were not; and any ex parte communications between DEA and third parties.
"Without knowing who DEA excluded and why, there is no way to assess whether and to what extent the Agency's decisions are arbitrary and capricious, the subject of bias, or otherwise unlawful," reads the filing. "If, for example, DEA included parties with expertise on a particular topic but only if they opposed the Proposed Rule while also excluding parties with even more expertise on that same topic if they supported the Proposed Rule, then there would be a powerful case to be made that the Agency's decisions were arbitrary and capricious."
Among 25 participants that DEA chose to join the hearing on rescheduling cannabis is Smart Approaches To Marijuana (SAM), an organization opposed to marijuana legalization and commercialization. On the other hand, Village Farms is <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">the only cannabis operator selected to represent cannabis industry</a>.
Village Farms and Hemp for Victory also require that SAM and the DEA be ordered to preserve their records, as factual evidence demonstrates unlawful conduct which has further compromised the DEA's participation in the proceedings.
Michael DeGiglio, retired Navy captain and naval aviator and president and chief executive officer of Village Farms concluded, "Our organization embraces the power of the cannabis plant as an alternative to Big Pharma and harmful, addicting drugs like opioids. However, we continue to face burdensome challenges in several of our regulatory jurisdictions that not only restrict us from advancing access to cannabis for millions of people, but have also created near-insurmountable institutional barriers to clinical research involving cannabis. We are proud to be one of the pro-cannabis participants selected to testify as a witness in the upcoming Rescheduling Hearing, but the filing of this joint motion reflects our desire for a more transparent process that ensures all credible voices are heard, including other applicants whose expertise has been overlooked or ignored."
<h2 class="wp-block-heading">DEA Under Attack</h2>
The motion follows a lawsuit by a Washington-based researcher filing a <a href="https://www.benzinga.com/news/legal/24/11/41923948/dea-faces-lawsuit-alleging-bias-in-marijuana-rescheduling-process">lawsuit against the DEA alleging multiple legal violations</a> in the agency&#8217;s process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling" target="_blank" rel="noreferrer noopener">rescheduling marijuana</a>. David Heldreth, CEO of psychedelic research firm Panacea Plant Sciences, claims the DEA&#8217;s recent actions violate federal law and constitutional principles. Despite submitting a request to participate in the hearings, Heldreth&#8217;s company, Panacea Plant Sciences, was excluded from the list of 25 participants chosen by Milgram. This exclusion is at the heart of Heldreth&#8217;s lawsuit, which accuses the DEA of bias and of sidelining critical voices in favor of larger, established players in the industry.
Moreover, the Veterans Action Council (VAC), a cannabis advocacy organization for military vets, <a href="http://drugsense.org/temp/VACXPRESSXXRELEASE_X14XNovemberXX2024.pdf?fbclid=IwZXh0bgNhZW0CMTAAAR1wzl2RC2z5p-kEiG9p4J03gHKGhie0JyDYxWJx3SdVSeDA7a_6WeEXL3Y_aem_ANUFL62rwPZ-jy58Hyw9-A" target="_blank" rel="noreferrer noopener">filed a petition</a> also <a href="https://www.benzinga.com/news/legal/24/11/42068859/veterans-group-challenges-dea-for-seat-at-cannabis-debate-table">challenging its exclusion</a> from the DEA&#8217;s participant list. VAC contends that the DEA failed to meet its obligation to include all interested parties. &#8220;The DEA was tasked with putting forward a group of ‘interested parties.&#8217; They failed to do so, as illustrated by the judge&#8217;s recent order,&#8221; said VAC&#8217;s Michael Krawitz.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39215651/dea-ditches-high-level-federal-health-meeting-on-cannabis-research-another-expression-of-distast">DEA Ditches High-Level Federal Health Meeting On Cannabis Research: Another Expression Of Distaste For Cannabis Rescheduling?</a></li>
</ul>
Photo: Courtesy of RazorMax and ganjaspliffstoreuk to Pixabay

Cannabis

DEA Is Compromised, DOJ Should Replace It In Cannabis Rescheduling, Claims Joint Motion

Leading Domestic Manufacturer and Brewer Continues Ongoing Investments&nbsp;in its Communities, Building on $2 Billion Spend Over Last 5 Years&nbsp;&nbsp;&nbsp;
HOUSTON, Nov. 20, 2024 &nbsp;/PRNewswire/ -- Anheuser-Busch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>), a leading domestic manufacturer and brewer of Michelob ULTRA, Busch Light, Budweiser, and Bud Light, today announced a new $14 million investment in its Houston brewery. Over the last 5 years, Anheuser-Busch has invested nearly $2 billion in its facilities across the country to help create and sustain jobs and drive economic prosperity in the communities where it operates and its employees call home.&nbsp;&nbsp;

Anheuser-Busch Invests $14M In Its Houston Brewery To Drive Economic Growth; To Help Create And Sustain Jobs And Drive Economic Prosperity In The Communities Where It Operates

Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) shares are trading lower by 3.04% to $14.68 during Wednesday&#8217;s session, reflecting broader retail sector jitters after Target Corporation released disappointing <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">third-quarter earnings</a>.
What To Know: Target missed Wall Street estimates for both revenue and earnings per share, citing cost pressures and challenges related to inventory and supply chain management. The retail giant also lowered its full-year profit outlook, signaling caution heading into the crucial holiday season.
The ripple effects of Target's report are likely weighing on Macy's as investors brace for potential parallels in performance. Target's challenges, such as increased digital fulfillment costs and inventory pressures, may mirror broader trends impacting department stores, which have also been grappling with shifting consumer behavior and rising costs.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42090657/microstrategy-upsizes-convertible-notes-offering-to-2-6-billion-for-bitcoin-purchases">MicroStrategy Upsizes Convertible Notes Offering To $2.6 Billion For Bitcoin Purchases</a>
Additionally, Target's lowered guidance suggests potential headwinds for discretionary spending, a vital revenue driver for Macy's.
Target's results highlighted that while beauty and essentials categories grew, comparable sales across other segments were modest, raising concerns about retail demand. Macy's, heavily reliant on apparel and home goods, is particularly sensitive to shifts in consumer spending priorities. 
The cautious sentiment could pressure Macy's shares as investors reassess retail earnings prospects in a challenging economic environment.
Read Also: <a href="https://www.benzinga.com/tech/24/11/42086154/apple-to-argue-for-dismissal-of-doj-antitrust-case-over-alleged-us-smartphone-market-domination">Apple To Argue For Dismissal Of DOJ Antitrust Case Over Alleged US Smartphone Market Domination</a>
<h2 class="wp-block-heading">How To Buy M Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Macy&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Macy&#8217;s has a 52-week high of $22.10 and a 52-week low of $14.06.

Why Macy's Stock Is Falling

QCOM

Qualcomm CEO Says Right Now No Large Acquisitions Identified

RBC Capital analyst Steven Shemesh maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Sector Perform and raises the price target from $290 to $291.

RBC Capital Maintains Sector Perform on Lowe's Companies, Raises Price Target to $291

XCUR

Exicure Shares Halted On Circuit Breaker To The Upside, Stock Now Up 82.1%

AEye, Inc. (LIDR) Q4 2023 Earnings Call Transcript

AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript

AEye, Inc. (LIDR) Q2 2024 Earnings Call Transcript

AEye, Inc. 2024 Q3 - Results - Earnings Call Presentation

AEye, Inc. (LIDR) Q3 2024 Earnings Call Transcript

LIDR

LIDRW

Advanced Energy Industries, Inc. - Common Stock

Advanced Energy Indus

PowerFleet

Arlo Technologies

Badger Meter

Cognex

Crane NXT

Daktronics

Evolv Technologies Holdings, Inc. - Class A Common Stock

Evolv Technologies

Faro Technologies

Itron

Keysight Techs

nLight

AEye

Mirion Technologies, Inc. Class A Common Stock

Mirion Technologies

Novanta

NAPCO Security Technologies, Inc. - Common Stock

NAPCO Security Techs

NOVONIX Limited - American Depository Shares

NOVONIX

OSI Systems

Ouster

PAR Technology

Red Cat Hldgs

SmartRent

Teledyne Technologies Incorporated Common Stock

Teledyne Technologies

Trimble

Vontier

Vishay Precision Group, Inc. Common Stock

Vishay Precision Group

Zebra Technologies Corporation - Class A Common Stock

Comments

AEye

News

Latest news for AEye (NASDAQ:LIDRW) Stock

Wednesday, December 27, 2023

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga